Targeting molecular resistance in castration-resistant prostate cancer

Thenappan Chandrasekar, Joy C. Yang, Allen C Gao, Christopher P Evans

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

Multiple mechanisms of resistance contribute to the inevitable progression of hormone-sensitive prostate cancer to castration-resistant prostate cancer (CRPC). Currently approved therapies for CRPC include systemic chemotherapy (docetaxel and cabazitaxel) and agents targeting the resistance pathways leading to CRPC, including enzalutamide and abiraterone. While there is significant survival benefit, primary and secondary resistance to these therapies develops rapidly. Up to one-third of patients have primary resistance to enzalutamide and abiraterone; the remaining patients eventually progress on treatment. Understanding the mechanisms of resistance resulting in progression as well as identifying new targetable pathways remains the focus of current prostate cancer research. We review current knowledge of mechanisms of resistance to the currently approved treatments, development of adjunctive therapies, and identification of new pathways being targeted for therapeutic purposes.

Original languageEnglish (US)
Article number206
JournalBMC Medicine
Volume13
Issue number1
DOIs
StatePublished - Sep 1 2015

Fingerprint

Castration
Prostatic Neoplasms
docetaxel
Therapeutics
Hormones
Drug Therapy
Survival
Research

Keywords

  • Castration-resistant
  • Disease progression
  • Drug resistance
  • Prostatic neoplasms

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Targeting molecular resistance in castration-resistant prostate cancer. / Chandrasekar, Thenappan; Yang, Joy C.; Gao, Allen C; Evans, Christopher P.

In: BMC Medicine, Vol. 13, No. 1, 206, 01.09.2015.

Research output: Contribution to journalArticle

@article{56dcdbbc4fbc412d9116c3a1c486141e,
title = "Targeting molecular resistance in castration-resistant prostate cancer",
abstract = "Multiple mechanisms of resistance contribute to the inevitable progression of hormone-sensitive prostate cancer to castration-resistant prostate cancer (CRPC). Currently approved therapies for CRPC include systemic chemotherapy (docetaxel and cabazitaxel) and agents targeting the resistance pathways leading to CRPC, including enzalutamide and abiraterone. While there is significant survival benefit, primary and secondary resistance to these therapies develops rapidly. Up to one-third of patients have primary resistance to enzalutamide and abiraterone; the remaining patients eventually progress on treatment. Understanding the mechanisms of resistance resulting in progression as well as identifying new targetable pathways remains the focus of current prostate cancer research. We review current knowledge of mechanisms of resistance to the currently approved treatments, development of adjunctive therapies, and identification of new pathways being targeted for therapeutic purposes.",
keywords = "Castration-resistant, Disease progression, Drug resistance, Prostatic neoplasms",
author = "Thenappan Chandrasekar and Yang, {Joy C.} and Gao, {Allen C} and Evans, {Christopher P}",
year = "2015",
month = "9",
day = "1",
doi = "10.1186/s12916-015-0457-6",
language = "English (US)",
volume = "13",
journal = "BMC Medicine",
issn = "1741-7015",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Targeting molecular resistance in castration-resistant prostate cancer

AU - Chandrasekar, Thenappan

AU - Yang, Joy C.

AU - Gao, Allen C

AU - Evans, Christopher P

PY - 2015/9/1

Y1 - 2015/9/1

N2 - Multiple mechanisms of resistance contribute to the inevitable progression of hormone-sensitive prostate cancer to castration-resistant prostate cancer (CRPC). Currently approved therapies for CRPC include systemic chemotherapy (docetaxel and cabazitaxel) and agents targeting the resistance pathways leading to CRPC, including enzalutamide and abiraterone. While there is significant survival benefit, primary and secondary resistance to these therapies develops rapidly. Up to one-third of patients have primary resistance to enzalutamide and abiraterone; the remaining patients eventually progress on treatment. Understanding the mechanisms of resistance resulting in progression as well as identifying new targetable pathways remains the focus of current prostate cancer research. We review current knowledge of mechanisms of resistance to the currently approved treatments, development of adjunctive therapies, and identification of new pathways being targeted for therapeutic purposes.

AB - Multiple mechanisms of resistance contribute to the inevitable progression of hormone-sensitive prostate cancer to castration-resistant prostate cancer (CRPC). Currently approved therapies for CRPC include systemic chemotherapy (docetaxel and cabazitaxel) and agents targeting the resistance pathways leading to CRPC, including enzalutamide and abiraterone. While there is significant survival benefit, primary and secondary resistance to these therapies develops rapidly. Up to one-third of patients have primary resistance to enzalutamide and abiraterone; the remaining patients eventually progress on treatment. Understanding the mechanisms of resistance resulting in progression as well as identifying new targetable pathways remains the focus of current prostate cancer research. We review current knowledge of mechanisms of resistance to the currently approved treatments, development of adjunctive therapies, and identification of new pathways being targeted for therapeutic purposes.

KW - Castration-resistant

KW - Disease progression

KW - Drug resistance

KW - Prostatic neoplasms

UR - http://www.scopus.com/inward/record.url?scp=84940508576&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84940508576&partnerID=8YFLogxK

U2 - 10.1186/s12916-015-0457-6

DO - 10.1186/s12916-015-0457-6

M3 - Article

C2 - 26329698

AN - SCOPUS:84940508576

VL - 13

JO - BMC Medicine

JF - BMC Medicine

SN - 1741-7015

IS - 1

M1 - 206

ER -